Obesity and cardiovascular hemodynamic function

被引：19

作者：

Koch R. ^{[1
]}

Sharma A.M. ^{[1
]}

机构：

[1] Medizinische Klinik, Klinkum Benjamin Franklin, Free University of Berlin, Hindenburgdamm 30, D-12200, Berlin

来源：

Current Hypertension Reports | 1999年 / 1卷 / 2期

关键词：

Left Ventricle; Left Atrial; Atrial Natriuretic Peptide; Dexfenfluramine; Concentric Hypertrophy;

D O I：

10.1007/s11906-999-0006-9

中图分类号：

学科分类号：

摘要：

Marked abnormalities in cardiovascular structure and hemodynamic function are present both in normotensive and hypertensive obese individuals. Cardiac abnormalities include excentric left ventricular hypertrophy and left atrial dilatation, a finding compatible with the presence of cardiac volume overload. In contrast, hypertension, often associated with abdominal obesity, is characterized by increased peripheral resistance and concentric hypertrophy. Weight reduction can result in marked improvement of ventricular dimensions and cardiac function in patients undergoing massive weight reduction following bariatric surgery. In this paper we review recent findings that have broadened our understanding of cardiovascular hemodynamic function in obesity. Copyright © 1999 by Current Science Inc.

引用

页码：127 / 130

页数：3

共 23 条

[1]

Kortelainen, M.L., Association between cardiac pathology and fat tissue distribution in an autopsy series of men without premortem evidence of cardiovascular disease (1996) Int J Obes Relat Metab Disord, 20, pp. 245-252

[2]

De Simone, G., Devereux, R.B., Roman, M.J., Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults (1994) Hypertension, 23, pp. 600-606

[3]

Gottdiener, J.S., Reda, D.J., Williams, D.W., Materson, B.J., Left atrial size in hypertensive men: Influence of obesity, race and age. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents (1997) J Am Coll Cardiol, 29, pp. 651-658

[4]

Connolly, H.M., Crary, J.L., McGoon, M.D., Valvular heart disease associated with fenfluramine-phentermine (1997) N Engl J Med, 337, pp. 581-588

[5]

Khan, M.A., Herzog, C.A., St. Peter, J.V., The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetitesuppressant drug (1998) N Engl J Med, 339, pp. 713-718

[6]

Jick, H., Vasilakis, C., Weinrauch, L.A., A population-based study of appetite-suppressant drugs and the risk of cardiacvalve regurgitatio (1998) N Engl J Med, 339, pp. 719-724

[7]

Weissman, N.J., Tighe Jr., J.F., Gottdiener, J.S., Gwynne, J.T., An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group (1998) N Engl J Med, 339, pp. 725-732

[8]

Paulson, D.J., Tahiliani, A.G., Cardiovascular abnormalities associated with human and rodent obesity (1992) Life Sci, 51, pp. 1557-1569

[9]

De Simone, G., Devereux, R.B., Daniels, S.R., Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight (1997) Circulation, 95, pp. 1837-1843

[10]

Devereux, R.B., Roman, M.J., Paranicas, M., Relations of Doppler stroke volume and its components to left ventricular stroke volume in normotensive and hypertensive American Indians: The Strong Heart Study (1997) Am J Hypertens, 10, pp. 619-628

← 1 2 3 →